ESC: Amgen CMO flags Repatha 'inflection' amid new data on mortality benefit

On the back of a heart-helping win for the 11-year-old Repatha last fall, Amgen has continued to deepen the evidence on its PCSK9 inhibitor’s ability to cut cardiovascular risks in many patients.